<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101669</url>
  </required_header>
  <id_info>
    <org_study_id>18-1</org_study_id>
    <nct_id>NCT04101669</nct_id>
  </id_info>
  <brief_title>EndoBarrier System Pivotal Trial(Rev B)</brief_title>
  <acronym>STEP-1</acronym>
  <official_title>A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biostatistical Consulting, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GI Dynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier
      System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and
      Obesity, the STEP-1 Study.

      A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and
      effectiveness of the EndoBarrier System plus moderate intensity lifestyle and dietary
      counseling compliant with 2019 ADA Standard of Care as compared to a sham control receiving
      moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will
      practice medical management compliant with STEP-1 Study Guidelines. Patients will be
      randomized 3 (EndoBarrier):1 (Sham).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of the EndoBarrier
      System when used with moderate intensity lifestyle and dietary counseling and medical
      management, in patients with baseline HbA1c ≥ 8.0% and ≤10%, and BMI ≥ 30 kg/m2 and ≤
      50kg/m2, whose diabetes medications consist of at least triple therapy for 3 months,
      excluding insulin, yet have not achieved adequate HbA1c control (&lt;7%).

      Specific objectives of this study are:

        1. To determine if the EndoBarrier System significantly improves glycemic control

        2. To determine that the EndoBarrier System can be safely used to improve glycemic control
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the EndoBarrier System. Patients will be randomized 3 (EndoBarrier):1 (Sham).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The Investigators include interventional gastroenterologists (GI) and endocrinologists. The GI team: MD, PA and site coordinator, as well as radiology personnel will not be masked, while the endocrinologist team: the MDs, PAs, site coordinators and nutritionists, will be masked. The patient is also masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>One year</time_frame>
    <description>Change in HbA1c value from baseline to 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c value</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Proportion of patients who achieve an HbA1c value of &lt; 7 % by 12 months (52 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Proportion of patients who achieve percent total body weight loss ≥ 5% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin use</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Proportion of patients initiating insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in systolic blood pressure values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily fasting glucose level</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in fasting blood glucose values as measured by daily glucometer reading in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nonalcoholic Fatty Liver Disease (NAFLD)</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in NAFLD, change in % liver fat using MRI (proton density fat fraction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nonalcoholic Steatohepatitis (NASH)</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>NASH- liver fibrosis % compared to baseline using using MRE measured in kPa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in HOMA-IR (using fasting glucose and fasting insulin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change from baseline in treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire (DTSQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Risk Level of CKD eGFR</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Risk Level of CKD albumin</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in albumin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change in impact of weight on life from baseline using Weight on Quality of Life (IWQOL-lite)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Diabetes type2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>EndoBarrier</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in ARM 1, will receive an upper endoscopy and will be treated with the EndoBarrier Liner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the EndoBarrier Liner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoBarrier Liner</intervention_name>
    <description>The EndoBarrier System is provided as a single-use, sterile device and consists of an EndoBarrier Liner preloaded, packaged and sterilized within the EndoBarrier Delivery System. The EndoBarrier Delivery System is utilized to deliver the EndoBarrier Liner to the proximal small intestine. The EndoBarrier Liner is removed using the EndoBarrier Retrieval System. The EndoBarrier System incorporates no pharmacological, biological tissue or blood products.</description>
    <arm_group_label>EndoBarrier</arm_group_label>
    <other_name>EndoBarrier Sleeve</other_name>
    <other_name>Duodenal-jejunal Bypass Liner (DJBL)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Patient receives upper endoscopy but no treatment</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥30 years and ≤ 55 years

          2. Have understood and signed the approved informed consent form

          3. Diagnosis of type 2 diabetes for ≤ 15 years

          4. HbA1c ≥ 8.0% and ≤10%

          5. BMI ≥30kg/m2 and ≤ 50kg/m2

          6. Willing and able to comply with study requirements

          7. Documented negative pregnancy test in women of childbearing potential

          8. Women of childbearing potential not intending to become pregnant (continue to be on an
             approved form of birth control) for the duration of their trial participation,
             including post explant period. Women of child-bearing age without known sterilization
             will be placed on 2 forms of birth-control to prevent unwanted pregnancies

          9. At least one year of medical records available, including detailed medical therapy and
             dosing information

         10. Failed to achieve adequate HbA1c reduction (&lt;7%) after triple therapy for at least
             3-month stable dosage of diabetes medication(s), including metformin, SGLT-2
             inhibitor, GLP-1 RA or, other medications including meglitinides, sulfonylureas,
             thiazolidinediones, or DPP-4s. Use of insulin is an exclusion criterion. Patients
             should be at 70% of maximum dosage of diabetes medications or highest tolerable
             dosage.

        Exclusion Criteria:

          1. Previous treatment with the EndoBarrier System

          2. Previous GI surgery that could preclude the ability to place the EndoBarrier Liner or
             affect the function of the EndoBarrier Liner, or abnormal GI anatomical finding that
             could preclude the ability to place the EndoBarrier Liner or affect the function of
             the EndoBarrier Liner

          3. Known history of liver disease (e.g., viral, autoimmune, fibrosis/cirrhosis etiology,
             but not including incidental fatty liver)

          4. eGFR of less than 45 ml/min/1.73 m2

          5. Prior history of an abscess requiring hospitalization, intravenous antibiotics or
             drainage

          6. Previous treatment for severe liver disease and/or biliary tract disease, including
             but not limited to, surgery, bile duct dilatation, and stent placement

          7. Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis

          8. Fasting C-peptide &lt; 1.0 ng/mL

          9. Triglyceride level &gt; 600 mg/dL

         10. Vitamin D deficiency (&lt;30ng/ml)

         11. Male patients with serum creatinine (Cr) &gt;1.5 mg/dl or female patients with Cr &gt;1.4
             mg/dl

         12. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet
             count less than 100,000/microliter, or known coagulopathy

         13. Height &lt; 5 feet (152.4 cm)

         14. Current or past alcohol addiction, current or past drug addiction, or current drug
             usage, of drugs such as, narcotics, opiates, or benzodiazepines and other addictive
             tranquilizers

         15. History of pancreatitis

         16. Diagnosis of osteoporosis or currently taking bisphosphonates or teriparatide

         17. Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus,
             scleroderma)

         18. Active or recent (less than 12 months) gastroesophageal reflux disease (GERD) and
             utilizing PPI to treat.

         19. Thyroid disease

         20. Currently taking prescription antithrombotic therapy (e.g. anticoagulant or
             antiplatelet agent) within 10 days prior to randomization and/or there is a need or
             expected need to use during the trial 12 months post implant procedure

         21. Currently taking the following medications (within 30 days prior to randomization)
             and/or there is a need or expected need to use these medications during the trial 12
             months post index procedure:

             Restricted Medications/Supplements Systemic corticosteroids Proton Pump Inhibitor
             (PPI) Drugs known to affect GI motility (e.g.metoclopramide) Prescription or
             over-the-counter weight loss medication(s) Non-Steroidal Anti-Inflammatory Drugs
             (NSAIDs), aspirin, ibuprofen, and other anti-inflammatory medication for study
             duration Medications known to cause significant weight gain or weight loss (e.g.
             chemotherapeutics)

             Supplements that are known or suspected to increase bleeding risk including but not
             limited to:

             Gingko biloba Ginseng Vitamins C &amp; E Turmeric St. John's wort Evening primrose oil
             Feverfew Green Tea Extract

         22. Allergy or hypersensitivity to cephalosporins or penicillin and all equivalent
             antibiotics

         23. Active H. pylori

         24. History of Crohn's disease, atresias or untreated stenoses

         25. Abnormal pathologies or conditions of the gastrointestinal tract, including ulcers or
             upper gastrointestinal bleeding conditions within 3 months of randomization

         26. Any condition or major illness that places the patient at undue risk by participating
             in the study, including but not limited to, patients at significant risk for surgery
             because of potential need for surgery to address adverse events

         27. Poor dentition not allowing complete chewing of food

         28. Enrolled in another investigational study within 3 months of screening for this study
             (enrollment in observational studies is permitted)

         29. Residing in a location without ready access to study site medical resources

         30. Documented weight loss of 5% total body weight (TBW) anytime during the 3 months
             preceding randomization

         31. Positive Fecal Immunochemical Test (FIT) at time of screening

         32. History or observation of psychological disorder or behavior which could preclude
             compliance to the treatment and follow up plan

         33. No access to an active telephone and internet service for provision of Follow Up
             Schedule calls and electronic diary

         34. Having donated blood or received a blood transfusion in the 90 days prior to baseline
             labs. Patients should agree not to donate blood during the study

         35. Any condition that increases red cell turnover, such as thalassemia

         36. Existence of Pseudomonas, Stenotrophomonas, and/or Klebsiella as measured in oral or
             rectal swab

         37. A known sensitivity to nickel or titanium

         38. Do not meet the screening criteria for MRI (i.e., MRI unsafe, or MRI conditional but
             not appropriate for the region of interest)

         39. Current use of insulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher C Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen J Linhares, BS</last_name>
    <phone>774-454-3259</phone>
    <email>slinhares@gidynamics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Schorer, BA</last_name>
    <phone>774-454-7407</phone>
    <email>sschorer@gidynamics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Surgical Specialists of Louisianna</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Perilloux, BS, CCRC</last_name>
      <phone>877-691-3001</phone>
      <email>JPerilloux@whyweight.com</email>
    </contact>
    <contact_backup>
      <last_name>Jenny Richard</last_name>
      <phone>(877) 691-3001</phone>
      <email>jrichard@whyweight.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Lavin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James A Leithead, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuan-Huy Vu Tran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Talavera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Ryan, MS</last_name>
      <phone>617-525-8266</phone>
      <email>mryan@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aoife Devery, BSC</last_name>
      <phone>617-732-5174</phone>
      <email>adevery@bwh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher C Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lalita Khaodhiar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pichamol Jirapinyo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marvin Ryou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meghan Ariagno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Hathorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmad Bazarbashi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine, Division of Gastroenterology and Hepatology</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Korsnes, MA</last_name>
      <phone>734-647-3082</phone>
      <email>skorsnes@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adam Neidert, MS</last_name>
      <phone>734-615-0539</phone>
      <email>aneidert@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Allison R Schulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elif A Oral, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan J Law, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard s Kwon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew T Krafton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson University Hospital/Diabetes Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genine Jensen, RN</last_name>
      <phone>215-955-1978</phone>
      <email>Genine.Jensen@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marsha Simmons, BS, CCRP</last_name>
      <phone>215-955-8405</phone>
      <email>Marsha.Simmons@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Austin L Chiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric J Schiffrin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas E Kowalski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Schlachterman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David E Loren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge A Jabbour, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Mercado, BS</last_name>
      <phone>713-798-0950</phone>
      <email>Michael.Mercado@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wasif M Abidi, MD</last_name>
      <phone>713-798-0950</phone>
      <email>Wasif.Abidi@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wasif M Abidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kalpesh Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mandeep Bajaj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs311/en/index.html</url>
    <description>WHO. Fact Sheet 311:Obesity and overweight [internet] 2014</description>
  </link>
  <link>
    <url>http://www.asmbs.org/resources/estimate-of-bariatric-surgery-numbers</url>
    <description>Statistics on ASMBS 2016</description>
  </link>
  <link>
    <url>http://www.cycloset.com/hcp</url>
    <description>VeroScience L. Prescribing Information - Cycloset (bromocriptine mesylate) tablets. 2010</description>
  </link>
  <link>
    <url>http://www.hcp.tradjenta.com/dosing-administration/?sitelink=Dosing%252520Info&amp;gclid=EAIaIQobChMIqafSg5Lb5AIViJ-zCh1_ZQz5EAAYASABEgJSp_D_BwE&amp;gclsrc=aw.ds</url>
    <description>GmbH BII. Prescribing Information - Tradjenta (linagliptin) tablets 2011</description>
  </link>
  <link>
    <url>http://www.merckconnect.com/januvia/dosing-administration/</url>
    <description>Merck &amp; Co. I. Prescribing information: Januvia (sitagliptin) tablets. 2011:1-23.</description>
  </link>
  <reference>
    <citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.</citation>
    <PMID>18784090</PMID>
  </reference>
  <reference>
    <citation>Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009 Jun;11 Suppl 1:S55-67. doi: 10.1089/dia.2008.0132. Review. Erratum in: Diabetes Technol Ther. 2018 Apr;20(4):320.</citation>
    <PMID>19469679</PMID>
  </reference>
  <reference>
    <citation>Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12.</citation>
    <PMID>10938048</PMID>
  </reference>
  <reference>
    <citation>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558.</citation>
    <PMID>9742977</PMID>
  </reference>
  <reference>
    <citation>Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008 Jan;31(1):102-4. Epub 2007 Oct 12.</citation>
    <PMID>17934146</PMID>
  </reference>
  <reference>
    <citation>Detournay B, Cros S, Charbonnel B, Grimaldi A, Liard F, Cogneau J, Fagnani F, Eschwège E. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab. 2000 Nov;26(5):363-9.</citation>
    <PMID>11119015</PMID>
  </reference>
  <reference>
    <citation>Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003 Jan 1;289(1):76-9.</citation>
    <PMID>12503980</PMID>
  </reference>
  <reference>
    <citation>Torquati A, Lutfi R, Abumrad N, Richards WO. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg. 2005 Nov;9(8):1112-6; discussion 1117-8.</citation>
    <PMID>16269382</PMID>
  </reference>
  <reference>
    <citation>Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002 Nov;236(5):554-9. Review.</citation>
    <PMID>12409659</PMID>
  </reference>
  <reference>
    <citation>Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995 Apr 1;122(7):481-6.</citation>
    <PMID>7872581</PMID>
  </reference>
  <reference>
    <citation>Koh-Banerjee P, Wang Y, Hu FB, Spiegelman D, Willett WC, Rimm EB. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am J Epidemiol. 2004 Jun 15;159(12):1150-9.</citation>
    <PMID>15191932</PMID>
  </reference>
  <reference>
    <citation>Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care. 2011 May;34 Suppl 2:S330-4. doi: 10.2337/dc11-s242. Review.</citation>
    <PMID>21525478</PMID>
  </reference>
  <reference>
    <citation>Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2632-7.</citation>
    <PMID>17130196</PMID>
  </reference>
  <reference>
    <citation>Bennett MC, Badillo R, Sullivan S. Endoscopic Management. Gastroenterol Clin North Am. 2016 Dec;45(4):673-688. doi: 10.1016/j.gtc.2016.07.005. Review. Erratum in: Gastroenterol Clin North Am. 2017 Jun;46(2):xvii.</citation>
    <PMID>27837781</PMID>
  </reference>
  <reference>
    <citation>Brethauer SA, Chang J, Galvao Neto M, Greve JW. Gastrointestinal devices for the treatment of type 2 diabetes. Surg Obes Relat Dis. 2016 Jul;12(6):1256-61. doi: 10.1016/j.soard.2016.02.031. Epub 2016 Mar 2. Review.</citation>
    <PMID>27568475</PMID>
  </reference>
  <reference>
    <citation>Frattini F, Borroni G, Lavazza M, Liu X, Kim HY, Liu R, Anuwong A, Rausei S, Dionigi G. New endoscopic procedures for diabetes mellitus type 2 and obesity treatment. Gland Surg. 2016 Oct;5(5):458-464.</citation>
    <PMID>27867859</PMID>
  </reference>
  <reference>
    <citation>Laubner K, Riedel N, Fink K, Holl RW, Welp R, Kempe HP, Lautenbach A, Schlensak M, Stengel R, Eberl T, Dederichs F, Schwacha H, Seufert J, Aberle J. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. Diabetes Obes Metab. 2018 Aug;20(8):1868-1877. doi: 10.1111/dom.13300. Epub 2018 Apr 23.</citation>
    <PMID>29569313</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

